Our pipeline includes SYK, FLT3/AXL, EGFR mutants (single, double and triple), and FGFR4 signal network related disease pathways. Genosco’s core competence comes from its know-how in generating selective kinase inhibitor of interest.

Our most advanced pipeline is SKI-O-703, a selective SYK inhibitor for rheumatoid arthritis (RA), immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE) in its clinical phase 2. Our second generation SYK inhibitor to treat peripheral T-cell lymphoma caused by ITK-SYK, BTK inhibitor-insensitive diffuse large B-cell lymphoma (DLBCL) will be a desirable asset for immuno-oncology and is in lead selection stage.
SKI-G-801, an FLT3/AXL inhibitor for acute myeloid leukemia is in clinical phase 1 study.
GNS-1480 (Lazertinib,YH25448), an EGFR mutant-selective inhibitor for non-small cell lung cancer and its metastatic brain cancer is in clinical phase 1/2.
A selective FGFR4 inhibitor program for hepatocellular carcinoma is in lead optimization stage.